Innate Pharma: 33% response for IPH4502 at maximum dose in phase 1
Innate Pharma presented first phase 1 data for IPH4502, its antibody-drug conjugate targeting Nectin-4 and carrying an exatecan payload, at the EORTC-NCI-AACR symposium (ENA 2026) on 18 November 2026.
Antitumor activity was observed in several tumor types. In patients with urothelial cancer, this activity was measured at intermediate doses, none of them having received the maximum tolerated dose.
Activity observed in six patients at the maximum tolerated dose
The dose-escalation study included 76 patients with advanced solid tumors, treated at six dose levels between 0.6 and 3.6 mg/kg every three weeks. These patients had received a median of 3.5 prior lines of treatment and presented more than 10 tumor types. The primary objective of the study was tolerability.
At the maximum tolerated dose of 3.6 mg/kg, the objective response rate reached 33% in non-urothelial tumors, i.e., 2 patients out of 6. According to the company, responses were observed regardless of Nectin-4 expression level, whether low, moderate or high.
All 19 patients with urothelial cancer had previously received enfortumab vedotin. Fifteen were treated at 2.4 or 2.8 mg/kg and four at 3.2 mg/kg. Three partial responses were recorded, including one confirmed and two unconfirmed.
Tumor reduction was observed in the majority of these patients. The unconfirmed disease control rate stands at 68.4%, with a 95% confidence interval between 46.0% and 84.6%.
Grade 3 or higher adverse events in 43.4% of patients
As of the data cutoff date of 17 August 2026, the company described a well-tolerated product, with overall low hematologic toxicity. Stomatitis is the only dose-limiting toxicity reported. No febrile neutropenia or signal of peripheral neuropathy was observed.
Grade 3 or higher adverse events nevertheless occurred in 43.4% of patients, including grade 3 or higher anemia in 11.8%. Stomatitis affected 27.6% of patients, with 3.9% of grade 3 or higher cases.
These events led to dose reductions in 7.9% of patients and treatment discontinuations in 5.3%. The dose optimization phase, whose first patient is expected in the first half of 2027, will focus on urothelial cancer treated after enfortumab vedotin, in second line or beyond.
It will test fractionated administration on days 1 and 8 of each three-week cycle, with mandatory prophylaxis aimed at reducing stomatitis. "Our priority is now to optimize the dose and the administration schedule," said Jonathan Dickinson, chief executive officer, in order to guide the selection of a recommended phase 2 dose.